NUVARING 2.6 MG — DIN 02253186
ETHINYL ESTRADIOL : 2.6 MG ETONOGESTREL : 11.4 MG · ORGANON CANADA INC. · RING (SLOW-RELEASE) · wholesale supply in Canada
Health Canada status: MARKETED
What is NUVARING?
NUVARING 2.6 MG contains ETHINYL ESTRADIOL : 2.6 MG ETONOGESTREL : 11.4 MG. It is listed in the Health Canada Drug Product Database under DIN 02253186, held by ORGANON CANADA INC., supplied as RING (SLOW-RELEASE) for VAGINAL administration. Health Canada currently lists it as marketed, status dated 01-Feb-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NUVARING used for?
Conception control.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Vaginal Ring With Progestogen And Estrogen in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
3 holders have a Canadian DIN containing Vaginal Ring With Progestogen And Estrogen, across 3 DINs, of which 3 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| DUCHESNAY INC | 1 | 1 | RINGZA | Sourceable in Canada |
| ORGANON CANADA INC. | 1 | 1 | NUVARING | Sourceable in Canada |
| SEARCHLIGHT PHARMA INC | 1 | 1 | HALOETTE | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 2.6 MG |
|---|---|
| Dosage form | RING (SLOW-RELEASE) |
| Route | VAGINAL |
| Pack configuration (monograph) | Individually packaged in reclosable aluminum laminate sachets. Available in boxes of 1 or 3 sachets. |
| Storage | Not explicitly detailed in the provided snippet (section 11 header present but text cut off), though typically requires specific conditions for hormonal stability. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Vaginal Ring With Progestogen And Estrogen |
|---|---|
| ATC code | G02BB01 |
| AHFS class | 68:12.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02253186 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2253186 |
| Brand name | NUVARING |
| Generic / active ingredient | ETHINYL ESTRADIOL : 2.6 MG ETONOGESTREL : 11.4 MG |
| Market authorization holder | ORGANON CANADA INC. |
| Health Canada schedule | Prescription |
| ATC code | G02BB01 |
| ATC anatomical main group | G — Genito-urinary system and sex hormones |
| ATC therapeutic subgroup | G02BB |
| Current status | MARKETED |
| Status date | 01-Feb-2022 |
| Original market date | 2004-12-02 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
One ring inserted vaginally for 3 weeks, followed by a 1-week ring-free interval. Reinsert new ring no more than 1 week after removal. Check regularly for presence.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
History of venous/arterial thrombosis; severe hypertension; smoking over age 35; diabetes with vascular involvement; liver disease/tumors; known/suspected pregnancy; undiagnosed vaginal bleeding.
Warnings and precautions
Cigarette smoking increases risk of serious cardiovascular events, especially in women >35. Increased risk of VTE, MI, and stroke. Does not protect against STIs/HIV.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 3 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| HALOETTE | 11.7 MG | RING (SLOW-RELEASE) | SEARCHLIGHT PHARMA INC | MARKETED | 02520028 |
| RINGZA | 17.4 MG | RING (SLOW-RELEASE) | DUCHESNAY INC | MARKETED | 02554070 |
2 · Same class — other molecules in ATC G02BB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Vaginal Ring With Progestogen And Estrogen | HALOETTE · NUVARING · RINGZA | 3 | 3 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC G02B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| G02BA | Plastic Iud With Progestogens | 3 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.